Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial

Table 1 Study measurements

Examination by investigator	Objective symptoms (patient interview)
Physical examination	Body weight, blood pressure, pulse rate, 12-lead ECG
Hematological examination	WBC, RBC, Hb, Ht, PLT,
Hematological examination	Differential count of leukocytes (basophil, eosinophil, neutrophil, lymphocyte, monocyte)
Bleeding and coagulation test	PT, APTT
Blood biochemistry	TP, Alb, T-BIL, AST(GOT), ALT(GPT), ALP, LDH, γ-GTP,
	TCh, TG, UA, BUN, serum creatinine (SCr), Na, K, Cl, Ca, P, HbA1c, cystatin C,
	High-sensitive CRP
Uremia toxins test in plasma	Guanidino succinate
Urinalysis (occasional urine)	pH, qualitative protein, glucose, and urobilinogen, occult blood reaction urinary sediment (RBC, WBC, casts), β2 microglobulin (adjusted by creatinine), pregnancy test (hCG)
Urinalysis (24-hour pooled urine)	Urinary protein excretion, CCr, urea nitrogen, electrolytes (Na, Cl), urine output, creatinine

ISSN: 1471-2369